Cognitive and Metabolic Outcomes of Vildagliptin Addition to the Therapy in Patients with Type 2 Diabetes Mellitus: 26 Week Follow-up Study

Ates Bulut, Esra and Sahin Alak, Zehra Y. and Dokuzlar, Ozge and Kocyigit, Suleyman E. and Soysal, Pinar and Smith, Lee and Isik, Ahmet T. (2020) Cognitive and Metabolic Outcomes of Vildagliptin Addition to the Therapy in Patients with Type 2 Diabetes Mellitus: 26 Week Follow-up Study. Archives of Gerontology and Geriatrics, 88. p. 104013. ISSN 1872-6976

[img] Text
Accepted Version
Restricted to Repository staff only until 20 January 2021.
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (112kB)
Official URL: https://doi.org/10.1016/j.archger.2020.104013

Abstract

Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM. Materials and Methods: A retrospective longitudinal clinical trial was carried out on total 130 subjects with type 2 DM. Patients underwent comprehensive geriatric assessment twice within six months interval. The patients were divided into three groups according to antidiabetic treatment: untreated control group (patients achieve individual goal HbA1c without antidiabetic medication), vildagliptin(+) group(patients using vildagliptin alone or combination) and the vildagliptin(–) group. Results: The mean age was 75.72 ± 7.46 years. The control group was older, of a lighter weight and also had a higher female gender ratio(p ≤ 0.01). When sex, age, educational level and metabolic profile were adjusted, there was only change in copying subdomain of Mini Mental State Examination between vildagliptin(+) and other groups at the end of 6 months. Vildagliptin also resulted in reduction of HbA1c and weight(p<0.05). Conclusion: The addition of vildagliptin to treatment improved the copying subdomain of cognitive function and metabolic control of the older patients with type 2 DM within 6 months.

Item Type: Journal Article
Keywords: DPP-4 inhibitors, Cognitive decline, Metabolic outcomes, Diabetes mellitus, Alzheimer’s disease, Older adults
Faculty: Faculty of Science & Engineering
SWORD Depositor: Symplectic User
Depositing User: Symplectic User
Date Deposited: 20 Jan 2020 09:23
Last Modified: 03 Feb 2020 14:14
URI: http://arro.anglia.ac.uk/id/eprint/705110

Actions (login required)

Edit Item Edit Item